BRIEF published on 10/28/2025 at 17:55, 10 months 11 days ago FUTRUE ajuste la rémunération en espèces pour le retrait forcé de PharmaSGP Assemblée Générale Squeeze-out Compensation En Espèces PharmaSGP Futrue GmbH
BRIEF published on 10/28/2025 at 17:55, 10 months 11 days ago FUTRUE Adjusts Cash Compensation for PharmaSGP Squeeze-Out General Meeting Squeeze-out Cash Compensation PharmaSGP Futrue GmbH
PRESS RELEASE published on 10/28/2025 at 17:50, 10 months 11 days ago FUTRUE increases adequate cash compensation under the squeeze-out FUTRUE increases adequate cash compensation under squeeze-out for PharmaSGP Holding SE minority shareholders. Cash compensation raised to EUR 30.64 per share effective immediately Squeeze-out Minority Shareholders Cash Compensation PharmaSGP Holding SE FUTRUE
BRIEF published on 09/22/2025 at 15:20, 11 months 16 days ago PharmaSGP Calls Extraordinary General Meeting for Squeeze-out Decision General Meeting Squeeze-out Share Transfer PharmaSGP Futrue GmbH
BRIEF published on 09/22/2025 at 15:20, 11 months 16 days ago PharmaSGP convoque une assemblée générale extraordinaire pour prendre une décision de retrait obligatoire Assemblée Générale Transfert D'actions PharmaSGP Retrait Forcé Futrue GmbH
PRESS RELEASE published on 09/22/2025 at 15:15, 11 months 16 days ago PharmaSGP convenes extraordinary general meeting to resolve on Squeeze-out PharmaSGP Holding SE convenes an extraordinary general meeting to resolve on squeeze-out of remaining shareholders. Cash compensation specified at EUR 29.33 per share Extraordinary General Meeting Squeeze-out Cash Compensation PharmaSGP Holding SE Futrue GmbH
BRIEF published on 09/11/2025 at 09:05, 11 months 27 days ago PharmaSGP Releases Preliminary Half-Year Figures for 2025 Adjusted EBITDA Germany PharmaSGP OTC Pharmaceuticals 2025 Revenues
BRIEF published on 09/11/2025 at 09:05, 11 months 27 days ago PharmaSGP publie ses chiffres préliminaires du premier semestre 2025 Allemagne EBITDA Ajusté PharmaSGP Chiffre D'affaires 2025 Médicaments En Vente Libre
PRESS RELEASE published on 09/11/2025 at 09:00, 11 months 27 days ago PharmaSGP publishes preliminary half-year figures for 2025 PharmaSGP Holding SE releases preliminary half-year figures for 2025, showing a 13.0% revenue increase. Adjusted EBITDA declined slightly due to higher expenses. Forecast aims for continued growth amidst global uncertainties Adjusted EBITDA Revenue Increase Growth Forecast PharmaSGP Half-Year Figures
BRIEF published on 08/06/2025 at 16:21, 1 year 1 month ago PharmaSGP annonce sa radiation de la Bourse de Francfort Bourse Bourse De Francfort Radiation PharmaSGP Futrue GmbH
Published on 09/09/2026 at 00:35, 6 hours 37 minutes ago Troubadour Resources Announces Non-Brokered Unit Private Placement and Convertible Debenture Financing
Published on 09/09/2026 at 00:25, 6 hours 47 minutes ago Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress
Published on 09/08/2026 at 23:35, 7 hours 37 minutes ago The Western Investment Company of Canada Limited Announces Intention to Commence Normal Course Issuer Bid
Published on 09/08/2026 at 22:30, 8 hours 42 minutes ago Grid Metals Announces Positive Mineralogical Results at Falcon West, Engages SGS Canada for Ore Sorting Test Work, and Announces Investor Relations Agreements
Published on 09/08/2026 at 22:15, 8 hours 57 minutes ago GameSquare Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Published on 09/09/2026 at 07:05, 6 minutes ago TerraPay Connects its Wallet Interoperability Network, Xend to Alipay+, Strengthening Global Payments Interoperability
Published on 09/09/2026 at 07:00, 11 minutes ago DocMorris launches private placement of approx. CHF 100 million Convertible Bonds due 2031 to finance early repurchase of Convertible Bonds 2028
Published on 09/09/2026 at 07:00, 12 minutes ago BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028
Published on 09/09/2026 at 07:00, 12 minutes ago Medacta Group SA: Medacta Group SA reports above-market revenue growth of 9.7% in constant currency1 with a robust adjusted EBITDA margin of 27.8% in c.c.1 in H1 2026
Published on 09/09/2026 at 07:00, 12 minutes ago Holcim invests in Cloud Cycle to bring real-time machine learning to concrete delivery
Published on 09/08/2026 at 17:45, 13 hours 27 minutes ago DAMARTEX / Droits de vote bruts et réels au 31 août 2026
Published on 09/08/2026 at 17:45, 13 hours 27 minutes ago Chiffre d’affaires semestriel consolidé 2026 : 71,8 M€
Published on 09/08/2026 at 17:45, 13 hours 27 minutes ago Damartex / Résultats de l'exercice 2025-2026
Published on 09/08/2026 at 11:00, 20 hours 12 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 09/08/2026 at 11:00, 20 hours 12 minutes ago INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL
